Weak quarter owing to poor execution; strong orderbook position

- PSP's Q2FY23 results were not in line with EWM and street estimates. Revenue from operations degrew 8% YoY but increased a marginal 3% QoQ.
- EBITDA margins contracted nearly 300bps YoY and QoQ on account of lower-than-expected revenue and increase in employee costs and other expenses. Consequent to the decline in revenue and EBITDA, PAT was down 41% YoY and 26% QoQ to INR22 crore.
- Order inflow momentum remains strong as the company received orders worth INR962 crore during the quarter and expects orders of nearly INR2,500 crore for FY23E. Furthermore, the company has the highest ever orderbook of INR5,081 crore currently, which is expected to support revenue growth going ahead.
- We remain positive on PSP given the strong orderbook position and brisk execution capabilities. We maintain our BUY rating with a revised TP of INR694/share, implying a 19% upside from the current share price.

Weak operating performance in Q2FY23; management targets 20–25% annual revenue growth

PSP's revenue from operations degrew 8% YoY but increased 3% QoQ. The decline in revenue was primarily due to a prolonged monsoon in Gujarat and Uttar Pradesh affecting execution at sites. Moreover, as most projects were at the nascent stage of construction, the company could not ramp up execution. Despite the subdued execution, the management expects to achieve revenue guidance of INR2,200 crore in FY23E. We believe the revenue growth momentum will improve in 2HFY23E, led by its healthy orderbook position and brisk execution capabilities.

EBITDA margins also contracted around 300bps YoY and QoQ on account of lower-than-expected revenue and increase in employee costs and other expenses. We anticipate EBITDA margins to remain 12–13% going ahead.

Healthy orderbook position; strong order inflow in Q2FY23

PSP has the highest ever orderbook of INR5,081 crore currently, translating to healthy revenue visibility of 2.9x of the FY22 revenue. During the quarter, the company received order inflow of INR962 crore and has secured orders of INR1,857 crore thus far (including L1 of INR345 crore in Gujarat) against its full year guidance of around INR2,500 crore while maintaining guidance of steady annual growth of 20–25% in the orderbook. The company has a robust bidding pipeline and is well positioned to build the orderbook with the development of pre-qualification and government's continued focus on infrastructure creation. Counter Party wise Government projects comprised 56% of the orderbook in Q2FY23 compared with 68% in FY22.

Expected ramp up in precast facility

PSP completed a precast facility spanning 1.1mn sq ft in Q3FY22 with an investment of INR109cr and plans to expand it to 3mn sq ft in the near future. The precast facility is currently operating at 50% capacity with orders worth INR236 crore. Utilisation will rise to 80–90% with increased application of precast material in other projects.

Outlook and valuation; maintain BUY

Due to a weak operating performance in Q2FY23, we trimmed our revenue growth estimates by 7% for FY23. Furthermore, due to a decline in EBITDA margins, we lowered our expectation by 50bps in FY23E and 30bps in FY24E. Despite a weak operating performance in 1HFY23, we expect revenue and PAT to post a CAGR of 18% and 24%, respectively, during FY21–24E. We believe PSP would benefit from its strong orderbook position, healthy order inflow, lean balance sheet, comfortable working capital cycle and favourable outlook of the construction sector. PSP is currently trading at 10.9x of the FY24E EPS and we reiterate BUY on PSP and revise our target price to INR694, valuing it at 13x of the FY24E EPS.


Year to March	Q2FY23	Q2FY22	% change	Q1FY23	% change	FY22	FY23E	FY24E
Net Revenues (INRcr)	360	390	-8	348	3	1,748	2,002	2,381
EBITDA (INRcr)	39.5	54.7	-28	48	-17	259	250	308
Net profit (INRcr)	22	36	-41	29	-26	167	158	192
EBITDA Margin	11%	14%		14%		15%	13%	13%
PAT Margin	6%	9%		8%		10%	8%	8%
Diluted EPS (INR)	6	10	-41	8	-26	46	44	53
Diluted P/E (x)						12	12	10
EV/EBITDA (x)						7	7	6
ROCE (%)						32%	24%	24%

Edelweiss | WEALTH RESEARCH

Sandeep Raina Research Analyst Sandeep.Raina@edelweiss.in

CMP: INR 585 Rating: BUY Target Price: INR 694 Upside: 19% Date: October 19, 2022

Bloomberg:	PSPPL:IN
52-week range (INR):	448 / 684
Share in issue (crore):	3.6
M-cap (INRcr):	2,057
Promoter holding (%)	70.39



Weak quarter owing to poor execution; strong orderbook position

Key Management Commentary Highlights

Operating Performance

- PSP registered a decent overall operating performance in Q2FY23. Revenue growth primarily declined due to a prolonged monsoon in Uttar Pradesh and Gujarat resulting in lower-than-expected productivity and most orders being in the early stage of construction.
- EBITDA margins declined due to lower-than-expected revenue in Q2FY23.
- Consequent to lower operating margins, PAT margins also declined.
- The finance cost rose due to increase in short-term borrowings to fund the mobilisation of projects.
- The company expects operating performance to improve, led by its strong orderbook position.
- The company derived INR84 crore from projects in Uttar Pradesh and cumulative revenue of INR266 crore thus far.
- The company is likely to benefit from government focus on Infra and pickup in private capex.
- Management exepects employee expenses to revert back to around 4% of the revenue going ahead.

Order Book

- PSP achieved the highest order book of INR5,081 crore in Q2FY23. Of the projects, 56% are from government entities and the remaining from private entities.
- By geography, nearly 50% orders are from Gujarat, followed by 36% from Uttar Pradesh, 14% from Maharastra and remaining from Rajasthan and New Delhi.
- In H1FY23, PSP received new orders worth INR1,512 crore against orders of INR637 crore received during 1HFY22. The company was awarded 14 new projects.
- PSP has a strong bidding pipeline and has submitted the bid for Surat Municipal Corporation. However, since the company was the sole bidder, Surat Municipal Corporation will reinvite the bid.
- Projects from Bhiwandi and Pandharpur are still under the non-moving category. The Bhiwandi project is under arbitration and the matter will be heard in November 2022. Both the projects account for around 14% of the total orderbook.

Capex

• The company is not planning any major capex. The overall capex would remain 3–4% of the revenue.

Precast Facility

- The precast facility is currently operating at 50% capacity.
- Currently, the company has orders of INR263 crore in the precast facility.
- Utilisation will improve to 80–90% with increased application of precast material in other projects.

Debt Structure and Liquidity

- PSP has long-term outstanding debt of INR45 crore and short-term debt of INR117 crore. The short-term debt was primarily increased to fund the mobilisation of new projects.
- The company has total FDRs of INR333 crore, of which INR116 crore are free FDRs, INR199 crore are under lien and INR18 crore serve as securities and EMDs.
- The company has a comfortable working capital cycle of 30 days.
- The company has total fund-based and non-fund-based limits of INR1,047 crore, of which INR85 crore is FB and INR560 crore is NFB.

Guidance

- The company is confident of achieving INR2,200 crore in revenue in FY23.
- EBITDA margins are expected to remain 11–13%.
- Order inflow of atleast INR2,200 crore is expected in FY23.

Weak quarter owing to poor execution; strong orderbook position

Q2FY23 Result Highlights

Particulars	Q2FY23	Q2FY22	% change	Q1FY23	% change
Income from operations	360	390	-8	348	3
Cost of goods sold	293	315	-7	273	7
Gross Profit	67	75	-11	75	-10
Employee expenses	22	16	45	22	3
Other expenses	5	5	-1	5	-4
Total operating expenses	321	336	-5	300	7
EBITDA	39	55	-28	48	-17
Depreciation and amortization	9	7	29	9	4
EBIT	30	48	-36	39	-22
Interest expenses	7	4	85	6	26
Other income	6	4	43	6	13
РВТ	30	48	-39	39	-24
Provision for tax	8	12	-32	10	-20
Profit/Loss from Associates	0	0	-60	0	
Adjusted net profit	22	36	-41	29	-26
Extraordinary items/Adjustments	0	0		-	
Reported net profit	22	36	-41	29	-26
Number of shares (crore)	4	4		4	
Diluted EPS (INR)	6	10	-41	8	-26

Revised Estimates

	FY23E			FY24E		
	Previous	Revised	% change	Previous	Revised	% change
Sales	2,162	2,002	7%	2,381	2,381	0%
EBITDA	281	250	11%	316	308	2%
EBITDA margin	13%	13%	-50bps%	13%	13%	-30bps%
PAT	181	158	13%	198	192	3%
EPS	50.3	43.8	13%	54.9	53.4	3%

Weak quarter owing to poor execution; strong orderbook position

Previous outlook

Q1FY23: At CMP, the stock is trading at 10.9x FY24E EPS. The company reported decent execution and a robust bid pipeline in Q1FY23. We anticipate revenue and PAT to increase at a CAGR of 24% and 34%, respectively, during FY21–24E. PSP also enjoys a healthy balance sheet, better working capital and improved return ratios. We maintain our 'BUY' rating with a target price of INR715 (13x FY24E EPS).

Q4FY22: At CMP, the stock is trading at 9.4x FY24E EPS. The company reported strong execution and a robust bid pipeline in Q4FY22. We anticipate revenue and PAT to increase at a CAGR of 24% and 34%, respectively, during FY21–24E. PSP also enjoys a healthy balance sheet, better WC and improved return ratios. We maintain our BUY rating with price target of INR715 (13x FY24 EPS).







Weak quarter owing to poor execution; strong orderbook position

Edelweiss | WEALTH RESEARCH

Financials

Income Statement					
Year to March (INR Cr)	FY20	FY21	FY22	FY23E	FY24E
Income from operations	1,499	1,241	1,748	2,002	2,381
Direct Expenses	535	396	499	731	859
Employee Cost	59	51	72	80	95
Other Expenses	714	659	918	941	1,119
Total operating expenses	1,309	1,106	1,490	1,752	2,073
EBITDA	191	135	259	250	308
Depreciation and amortisation	27	26	32	42	52
EBIT	164	109	227	208	257
Interest expenses	15	15	26	20	25
Other income	24	17	22	22	25
Profit before tax	173	111	222	210	257
Provision for tax	45	28	55	53	64
Core profit	128	83	167	158	192
Extraordinary items	0	-3	0	0	0
Profit after tax	128	81	167	158	192
Minority Interest	0	0	0	0	0
Share from associates	-0	-2	0	0	0
Adjusted net profit	128	78	167	158	192
Equity shares outstanding (Crs)	3.6	3.6	3.6	3.6	3.6
EPS (INR) basic	35.6	21.7	46.3	43.8	53.4
Diluted shares (Crs)	3.6	3.6	3.6	3.6	3.6
EPS (INR) fully diluted	35.6	21.7	46.3	43.8	53.4
Dividend per share	0.0	0.0	0.0	0.0	0.0
Dividend payout (%)	0.0	0.0	0.0	0.0	0.0

Common size metrics- as % of net revenues

Year to March	FY20	FY21	FY22	FY23E	FY24E
Operating expenses	87.3	89.1	85.2	87.5	87.1
Depreciation	1.8	2.1	1.8	2.1	2.2
Interest expenditure	1.0	1.2	1.5	1.0	1.1
EBITDA margins	12.7	10.9	14.8	12.5	13.0
Net profit margins	8.5	6.3	9.5	7.9	8.1

Growth metrics (%)

Year to March	FY20	FY21	FY22	FY23E	FY24E
Revenues	42.7	(17.2)	40.9	14.5	19.0
EBITDA	28.3	(29.2)	91.9	(3.3)	23.2
РВТ	26.1	(36.0)	100.2	(5.2)	21.9
Net profit	43.7	(38.9)	113.0	(5.3)	21.9
EPS	43.7	(38.9)	113.0	(5.3)	21.9

Weak quarter owing to poor execution; strong orderbook position

As on 31st March (INR Cr)	FY20	FY21	FY22E	FY23E	FY24E
Equity share capital	36	36	36	36	36
Warrants	0	1	2	3	3
Reserves & surplus	418	500	585	744	936
Shareholders funds	454	538	623	783	975
Borrowings	78	75	75	75	75
Minority interest	1	2	3	4	4
Sources of funds	533	616	703	864	1,057
Gross block	198	229	319	419	519
Depreciation	92	113	145	187	239
Net block	106	116	174	232	280
Capital work in progress	3	42	0	0	0
Total fixed assets	110	158	174	232	280
Goodwill	0	0	0	0	0
Non Current Assets	156	141	151	161	171
Inventories	97	89	100	146	192
Sundry debtors	235	227	291	334	376
Cash and equivalents	197	229	211	224	278
Loans and advances	135	121	0	0	0
Other current assets	34	27	178	214	257
Total current assets	698	693	780	917	1,103
Sundry creditors and others	229	260	273	300	327
Other Current Liabilities	200	64	131	152	176
Provisions	1	1	0	0	0
Total CL & provisions	430	325	405	452	504
Net current assets	269	368	376	465	600
Net Deferred tax	0	0	0	0	0
Misc expenditure	0	0	0	0	0
Uses of funds	533	616	703	864	1,057
Book value per share (INR)	148	171	195	240	294

Cash flow statement

Year to March (INR Cr)	FY20	FY21	FY22E	FY23E	FY24E
Net profit	128	81	167	158	192
Add: Depreciation	27	26	32	42	52
Add: Interest net of tax	11	11	19	15	19
Add: Deferred tax	0	1	2	3	3
Add: Others	20	12	0	0	0
Gross cash flow	186	130	220	217	266
Less: Changes in W. C.	171	56	82	77	80
Operating cash flow	19	71	138	140	186
Less: Capex	31	31	92	100	100
Less: Investment in subsidiaries	0	0	0	0	0
Free cash flow	-12	40	47	40	86

Weak quarter owing to poor execution; strong orderbook position

Ratios					
Year to March	FY20	FY21	FY22	FY23E	FY24E
ROAE (%)	28%	15%	27%	20%	20%
ROACE (%)	31%	18%	32%	24%	24%
Debtors (days)	57	67	61	61	58
Current ratio	1.6	1.8	1.9	2.0	2.2
Gross Debt/Equity	0.0	0.0	0.1	0.1	0.1
Inventory (days)	24	26	21	27	30
Payable (days)	53	76	57	55	50
Cash conversion cycle (days)	28	16	25	33	37
Gross Debt/EBITDA	0.0	0.0	0.3	0.3	0.2
Net debt/Equity	(0.4)	(0.4)	(0.2)	(0.2)	(0.2)

Valuation parameters

Year to March	FY20	FY21	FY22	FY23E	FY24E
Diluted EPS (INR)	35.6	22.4	46.3	43.8	53.4
Y-o-Y growth (%)	43.7	(37.1)	106.7	(5.3)	21.9
CEPS (INR)	43.0	29.6	55.2	55.5	67.9
Diluted P/E (x)	11.2	19.4	11.8	12.5	10.2
Price/BV(x)	3.2	2.9	3.1	2.5	2.0
EV/Sales (x)	0.8	1.1	1.0	0.9	0.7
EV/EBITDA (x)	6.5	9.9	7.1	7.3	5.7
Diluted shares O/S	3.6	3.6	3.6	3.6	3.6
Basic EPS	35.6	22.4	46.3	43.8	53.4
Basic PE (x)	11.2	19.4	11.8	12.5	10.2
Dividend yield (%)	0%	0%	0%	0%	0%

Edelweiss | WEALTH RESEARCH

Weak quarter owing to poor execution; strong orderbook position

_		_			
Т				2	5
	с.		-	а	

lead of Research lead - Fundamental lead - Trading ractice Head - Trading
lead - Trading
5
ractice Head - Trading
hief Economist
nfra, Real Estate, Hotels
onsumer Durables, Building materials, Healthcare
ervices, Hospitality
onsumption, Textile, QSR, Retail
FSI, NBFC
FSI, NBFC
harma, Chemicals
ement, Logistics, Mid-caps
Γ, Capital Goods, Defence
Aetals, Mid- Caps
echnical Analyst
)ption Trader
Aid Caps

Sales Team	Location
Sharad Tripathi	Mumbai
Ketan Malkan	Mumbai
Vikas Sharma	Bengaluru
Abhishek Agarwal	Kolkata
Vivek Khanna	Delhi

Coverage Universe

Sr. No	Coverage
1	Aditya Birla Fashion & Retail Ltd
2	Aegis Logistics Ltd
3	Amber Enterprises India Ltd
4	Astral Ltd
5	Balaji Amines Ltd
6	Bata India Ltd
7	Birla Corporation Limited
8	Can Fin Homes Ltd
9	Century Plyboards India Ltd
10	Cholamandalam Inv and Finance Ltd
10	City Union Bank Ltd
12	CreditAccess Grameen Ltd
13	Crompton Greaves Consumer Electricals Ltd
13	CSB Bank Ltd
14	Deepak Nitrite Ltd
15	Easy Trip Planner Ltd
17	Escorts Ltd
18	Finolex Industries Ltd
19	Home First Finance Company India Ltd
20	Indo Count Industries Ltd
20	K P R Mill Ltd
22	KNR Constructions Ltd
23	Krishna Institute of Medical Sciences Ltd
24	Lumax Industries. Ltd
25	Metropolis Healthcare Ltd
26	Minda Industries Ltd
27	Motherson Sumi Ltd
28	Navin Fluorine International Ltd
29	Neogen Chemicals Ltd
30	Newgen Software Technologies Ltd
31	Orient Electric Ltd
32	PSP Projects Ltd
33	Rossari Biotech Ltd
34	Shriram Transport Finance Company Ltd
35	SRF Ltd
36	Vinati Organics Ltd
37	Voltas Ltd
38	Westlife Development Ltd
39	Zydus Wellness Ltd
40	Tarsons Products Ltd
41	MTAR Technologies Ltd.
42	S J S Enterprises Ltd
	· · · ·

Sr. No	Tactical Buy
1	ACC Ltd
2	Ajanta Pharma Ltd
3	Ambuja Cements Ltd
4	Ashok Leyland Ltd
5	Axis Bank Ltd
6	Bharat Electronics Ltd
7	Brigade Enterprises Ltd
8	DLF Ltd
9	eClerx Services Ltd
10	Globus Spitits Ltd
11	GNA Axles Ltd
12	HDFC Life Insurance Co. Ltd
13	ICICI Bank Ltd
14	Indusind Bank Ltd
15	Jamna Auto Industries Ltd
16	JK Cement Ltd
17	Larsen & Toubro Ltd
18	Mahindra and Mahindra Ltd
19	Max Financial Services Ltd
20	Max Healthcare Institute Ltd
21	PNC Infratech Ltd
22	RBL Bank Ltd
23	Sun Pharma Ltd
24	TechMahindra Ltd
25	Ultratech Cement Ltd
26	Elecon Engineering Company Ltd
27	Kennametal India Ltd
-	



Edelweiss Broking Limited, 1st Floor, Tower 3, Wing B, Kohinoor City Mall, Kohinoor City, Kirol Road, Kurla(W) Board: (91-22) 4272 2200

Vinay Khattar

Head Research

vinay.khattar@edelweiss.in

Edelweiss Broking Limited ("EBL" or "Research Entity") is regulated by the Securities and Exchange Board of India ("SEBI") and is licensed to carry on the business of broking, depository services and related activities. The business of EBL and its associates are organized around five broad business groups – Credit including Housing and SME Finance, Commodities, Financial Markets, Asset Management and Life Insurance. There were no instances of non-compliance by EBL on any matter related to the capital markets, resulting in significant and material disciplinary action during the last three years. This research report has been prepared and distributed by Edelweiss Broking Limited ("Edelweiss") in the capacity of a Research Analyst as per Regulation 22(1) of SEBI (Research Analysts) Regulations 2014 having SEBI Registration No. INH000000172.

Broking services offered by Edelweiss Broking Limited under SEBI Registration No.: INZ000005231 (Member of NSE, BSE, MCX and NCDEX). EBL CIN: U65100GJ2008PLC077462. Research services offered by Edelweiss Broking Ltd. under SEBI Registration No. INH000000172. Depository Participant SEBI Registration No.: IN-DP-656-2021 with NSDL having DP ID: IN302201 & IN303719 and with CDSL having DP ID: 12032300. Investor grievance resolution team: 040-41151621; Email ID: Helpdesk@edelweiss.in (for trading related) and dpservicesebl@edelweiss.in (for demat related). Name of the Compliance Officer for Trading & DP - Mr. Pranav Tanna, Email IDs: complianceofficer.ebl@edelweissfin.com / ebl.dpcompliance@edelweissfin.com. Edelweiss Broking Ltd. also acts in the capacity of distributor for Products such as OFS, Mutual Funds and NCD etc

Corporate Office: Edelweiss House, Off CST Road, Kalina, Mumbai - 400098, Contact 18001023335 / (022)-42722200 / 022-40094279.

This Report has been prepared by Edelweiss Broking Limited in the capacity of a Research Analyst having SEBI Registration No.INH000000172 and distributed as per SEBI (Research Analysts) Regulations 2014. This report does not constitute an offer or solicitation for the purchase or sale of any financial instrument or as an official confirmation of any transaction. The information contained herein is from publicly available data or other sources believed to be reliable. This report is provided for assistance only and is not intended to be and must not alone be taken as the basis for an investment decision. The user assumes the entire risk of any use made of this information. Each recipient of this report should make such investigation as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved), and should consult his own advisors to determine the merits and risks of such investment. The investment discussed or views expressed may not be suitable for all investors.

This information is strictly confidential and is being furnished to you solely for your information. This information should not be reproduced or redistributed or passed on directly or indirectly in any form to any other person or published, copied, in whole or in part, for any purpose. This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject EBL and associates / group companies to any registration or licensing requirements within such jurisdiction. The distribution of this report in certain jurisdictions may be restricted by law, and persons in whose possession this report comes, should observe, any such restrictions. The information given in this report is as of the date of this report and there can be no assurance that future results or events will be consistent with this information. This information is subject to change without any prior notice. EBL reserves the right to make modifications and alterations to this statement as may be required from time to time. EBL or any of its associates / group companies shall not be in any way responsible for any loss or damage that may arise to any person from any inadvertent error in the information contained in this report. EBL is committed to providing independent and transparent recommendation to its clients. Neither EBL nor any of its associates, group companies, directors, employees, agents or representatives shall be liable for any damages whether direct, indirect, special or consequential including loss of revenue or lost profits that may arise from or in connection with the use of the information. Our proprietary trading and investment businesses may make investment decisions that are inconsistent with the recommendations expressed herein. Past performance is not necessarily a guide to future performance. The disclosures of interest statements incorporated in this report are provided solely to enhance the transparency and should not be treated as endorsement of the views expressed in the report. The information provided in these reports remains, unless otherwise stated, the copyright of EBL. All layout, design, original artwork, concepts and other Intellectual Properties, remains the property and copyright of EBL and may not be used in any form or for any purpose whatsoever by any party without the express written permission of the copyright holders.

EBL shall not be liable for any delay or any other interruption which may occur in presenting the data due to any reason including network (Internet) reasons or snags in the system, break down of the system or any other equipment, server breakdown, maintenance shutdown, breakdown of communication services or inability of the EBL to present the data. In no event shall EBL be liable for any damages, including without limitation direct or indirect, special, incidental, or consequential damages, losses or expenses arising in connection with the data presented by the EBL through this report.

We offer our research services to clients as well as our prospects. Though this report is disseminated to all the customers simultaneously, not all customers may receive this report at the same time. We will not treat recipients as customers by virtue of their receiving this report.

EBL and its associates, officer, directors, and employees, research analyst (including relatives) worldwide may: (a) from time to time, have long or short positions in, and buy or sell the securities thereof, of company(ies), mentioned herein or (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the subject company/company(ies) discussed herein or act as advisor or lender/borrower to such company(ies) or have other potential/material conflict of interest with respect to any recommendation and related information and opinions at the time of publication of research report or at the time of public appearance. EBL may have proprietary long/short position in the above mentioned scrip(s) and therefore should be considered as interested. The views provided herein are general in nature and do not consider risk appetite or investment objective of any particular investor; readers are requested to take independent professional advice before investing. This should not be construed as invitation or solicitation to do business with EBL.

EBL or its associates may have received compensation from the subject company in the past 12 months. EBL or its associates may have managed or co-managed public offering of securities for the subject company in the past 12 months. EBL or its associates may have received compensation for investment banking or merchant banking or brokerage services from the subject company in the past 12 months. EBL or its associates may have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past 12 months. EBL or its associates may have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past 12 months. EBL or its associates have not received any compensation or other benefits from the Subject Company or third party in connection with the research report. Research analyst or his/her relative or EBL's associates may have financial interest in the subject company. EBL, its associates, research analyst and his/her relative may have other potential/material conflict of interest with respect to any recommendation and related information and opinions at the time of publication of research report or at the time of public appearance.

Participants in foreign exchange transactions may incur risks arising from several factors, including the following: (i) exchange rates can be volatile and are subject to large fluctuations; (ii) the value of currencies may be affected by numerous market factors, including world and national economic, political and regulatory events, events in equity and debt markets and changes in interest rates; and (iii) currencies may be subject to devaluation or government imposed exchange controls which could affect the value of the currency. Investors in securities such as ADRs and Currency Derivatives, whose values are affected by the currency of an underlying security, effectively assume currency risk.

Research analyst has served as an officer, director or employee of subject Company: No EBL has financial interest in the subject companies: No

Disclaimer

EBL's Associates may have actual / beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of research report.

Research analyst or his/her relative has actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of research report: No

EBL has actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of research report: No

Subject company may have been client during twelve months preceding the date of distribution of the research report.

There were no instances of non-compliance by EBL on any matter related to the capital markets, resulting in significant and material disciplinary action during the last three years.

A graph of daily closing prices of the securities is also available at www.nseindia.com

Analyst Certification:

The analyst for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

Additional Disclaimer for U.S. Persons

Edelweiss is not a registered broker – dealer under the U.S. Securities Exchange Act of 1934, as amended (the "1934 act") and under applicable state laws in the United States. In addition Edelweiss is not a registered investment adviser under the U.S. Investment Advisers Act of 1940, as amended (the "Advisers Act" and together with the 1934 Act, the "Acts), and under applicable state laws in the United States. Accordingly, in the absence of specific exemption under the Acts, any brokerage and investment services provided by Edelweiss, including the products and services described herein are not available to or intended for U.S. persons.

This report does not constitute an offer or invitation to purchase or subscribe for any securities or solicitation of any investments or investment services and/or shall not be considered as an advertisement tool. "U.S. Persons" are generally defined as a natural person, residing in the United States or any entity organized or incorporated under the laws of the United States. US Citizens living abroad may also be deemed "US Persons" under certain rules.

Transactions in securities discussed in this research report should be effected through Edelweiss Financial Services Inc.

Additional Disclaimer for U.K. Persons

The contents of this research report have not been approved by an authorised person within the meaning of the Financial Services and Markets Act 2000 ("FSMA"). In the United Kingdom, this research report is being distributed only to and is directed only at (a) persons who have professional experience in matters relating to investments falling within Article 19(5) of the FSMA (Financial Promotion) Order 2005 (the "Order"); (b) persons falling within Article 49(2)(a) to (d) of the Order (including high net worth companies and unincorporated associations); and (c) any other persons to whom it may otherwise lawfully be communicated (all such persons together being referred to as "relevant persons").

This research report must not be acted on or relied on by persons who are not relevant persons. Any investment or investment activity to which this research report relates is available only to relevant persons and will be engaged in only with relevant persons. Any person who is not a relevant person should not act or rely on this research report or any of its contents. This research report must not be distributed, published, reproduced or disclosed (in whole or in part) by recipients to any other person.

Additional Disclaimer for Canadian Persons

Edelweiss is not a registered adviser or dealer under applicable Canadian securities laws nor has it obtained an exemption from the adviser and/or dealer registration requirements under such law. Accordingly, any brokerage and investment services provided by Edelweiss, including the products and services described herein, are not available to or intended for Canadian persons.

This research report and its respective contents do not constitute an offer or invitation to purchase or subscribe for any securities or solicitation of any investments or investment services.

Disclosures under the provisions of SEBI (Research Analysts) Regulations 2014 (Regulations)

Edelweiss Broking Limited ("EBL" or "Research Entity") is regulated by the Securities and Exchange Board of India ("SEBI") and is licensed to carry on the business of broking, depository services and related activities. The business of EBL and its associates are organized around five broad business groups – Credit including Housing and SME Finance, Commodities, Financial Markets, Asset Management and Life Insurance. There were no instances of non-compliance by EBL on any matter related to the capital markets, resulting in significant and material disciplinary action during the last three years. This research report has been prepared and distributed by Edelweiss Broking Limited ("Edelweiss") in the capacity of a Research Analyst as per Regulation 22(1) of SEBI (Research Analysts) Regulations 2014 having SEBI Registration No.INH000000172.